DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD
Written by
American Journal Managed Care
Published
0
comments
0
min
DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).